NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on September 20, 2021, Roger Sidhu was granted a non-qualified stock option covering 161,300 shares of Brooklyn’s common stock (the “Time-Based Option”) and a restricted stock unit covering 80,650 shares of Brooklyn’s common stock (the “RSU”).
The Time-Based Option will have a per share exercise price equal to the closing price of a share of Brooklyn’s common stock on the NYSE American Stock Exchange on September 20, 2021. Of the shares covered by the Time-Based Option, twenty-five percent of the shares will vest on September 20, 2022, and 1/36 of the remaining shares will vest on the twentieth day of each calendar month from October 20, 2022 through September 20, 2025, in each case for so long as Dr. Sidhu provides continuous service to Brooklyn through the relevant vesting date.
The RSU will vest in four equal installments, with one-fourth of the shares covered by such RSU vesting on the anniversary of the grant date in each of 2022, 2023, 2024 and 2025, in each case for so long as Dr. Sidhu provides continuous service to Brooklyn through the relevant vesting date.
The unvested portion of the Time-Based Option and the RSU will terminate upon the termination of Dr. Sidhu’s employment with Brooklyn for any reason, subject to certain vesting acceleration provisions upon a qualifying termination, as described in his employment agreement with Brooklyn. Unless earlier terminated in accordance with their terms, each of the Time-Based Option and the RSU will otherwise expire on the tenth anniversary of the grant date and be subject to the terms and conditions of the respective option agreement approved by Brooklyn. Each of the Time-Based Option and the RSU is intended to constitute an “employment inducement grant” in accordance with the employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, and is offered as an inducement material to Dr. Sidhu in connection with Brooklyn’s hiring of Dr. Sidhu. Both of the equity awards described above were granted pursuant to the Company’s 2021 Inducement Stock Incentive Plan, which was not subject to stockholder approval.
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.
Brooklyn’s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.
Investor Relations Contact:
CORE IR
516-222-2560
investors@brooklynitx.com
Media Contact:
CORE IR
Jules Abraham
917-885-7378
julesa@coreir.com
